In a case that could have broad ramifications for the pharmaceutical industry, a federal appeals court threw out the conviction of a sales rep who sold a drug for uses not approved by the FDA.
Ruling is a win for off-label marketing of drugs
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.